Kyverna Therapeutics, Inc. Common Stock

The lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action...

The article compares two biotech companies with contrasting profiles: Kyverna Therapeutics, a clinical-stage firm developing cell therapies for autoimmune diseases with no approved products and significant losses, versus Vertex Pharmaceuticals, an established leader generating $12 billion in revenue with a dominant cystic fibrosis franchise. The ...

Kyverna Therapeutics (KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases, announced upcoming presentations at the H.C. Wainwright 4th Annual Nasdaq BioConnect Conference on May 19th and the Jefferies Global Healthcare Conference on June 3rd, 2026. The company is advancing its lead CAR T-cell t...

Kyverna Therapeutics announced positive primary analysis results from its KYSA-8 registrational trial of miv-cel (mivocabtagene autoleucel) for stiff person syndrome (SPS). A single dose demonstrated statistically significant improvements across all primary and secondary endpoints at 16 weeks, with 81% of patients achieving clinically meaningful ...

Kyverna Therapeutics announced the appointments of Sravan K. Emany and Andrew Miller to its Board of Directors as the company advances toward commercialization of its cell therapies for autoimmune diseases. Emany, currently CFO of Beam Therapeutics, brings capital markets and rare disease expertise, while Miller, a Time Magazine honoree and forme...